Sign In
Buy MRNA
$51.59
+2.53 (+5.16%)
At Close: Jun 04, 2026
Moderna CEO Stephane Bancel on Q2 results, slashing its full-year sales guidance
08:30am, Thursday, 01'st Aug 2024
Moderna CEO Stephane Bancel joins 'Squawk Box' to discuss the company's quarterly earnings results, why the company is slashing its full-year sales guidance, state of the company's Covid vaccines, and
Moderna's stock slides 12% after it lowers full year sales guidance
06:41am, Thursday, 01'st Aug 2024
Moderna Inc.'s stock MRNA tumbled 12% premarket Thursday, after the biotech cut its sales guidance for 2024, offsetting a narrower-than-expected second-quarter loss and revenue that topped estimates.
Moderna beats estimates but slashes guidance on low EU sales, competitive U.S. vaccine market
06:34am, Thursday, 01'st Aug 2024
Moderna reported second-quarter revenue that beat estimates and a narrower than-expected loss for the period. But the company slashed its full-year sales guidance, citing lower sales in Europe, a "com
Moderna reins in 2024 sales forecast, expects very low EU vaccine revenue
06:33am, Thursday, 01'st Aug 2024
Moderna slashed its 2024 forecast for sales of its COVID-19 and respiratory syncytial virus vaccines by up to 25%, or $1 billion, on Thursday as it expects very low sales to the EU this year.
Moderna Reports Second Quarter 2024 Financial Results and Provides Business Updates
06:30am, Thursday, 01'st Aug 2024
Reports second quarter revenues of $241 million, GAAP net loss of $1.3 billion and GAAP EPS of $(3.33) Updates 2024 financial framework and revises expectations for product sales to $3.0 to $3.5 billi
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA
10:00am, Wednesday, 31'st Jul 2024
NEW YORK, NY / ACCESSWIRE / July 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Moderna, Inc. ("Moderna" or the "Company") (NASDAQ:MRNA). Such investors are advised to cont
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?
02:35pm, Tuesday, 30'th Jul 2024
Let's focus on biotech stocks like GSK, VRTX, BIIB, MRNA and REGN, which are scheduled to report this week.
Moderna: State Of Play Ahead Of Q2 Earnings, I'm (Temporarily) Pessimistic
11:10am, Tuesday, 30'th Jul 2024
Moderna will announce Q2 2024 earnings this Thursday, 1st August. Moderna stock hit highs of $450 per share in late 2021, but has since seen a decrease ~$120, and a current market cap valuation of ~$4
5 Biotech Stocks to Bet On Bright Industry Prospects
10:45am, Monday, 29'th Jul 2024
New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position MRNA, S
Exploring Analyst Estimates for Moderna (MRNA) Q2 Earnings, Beyond Revenue and EPS
10:22am, Monday, 29'th Jul 2024
Beyond analysts' top -and-bottom-line estimates for Moderna (MRNA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter
Get Your Money Out of These 3 Biotech Stocks Before the End of July
09:00am, Sunday, 28'th Jul 2024
Biotech stocks are known for their high volatility and potential for massive gains. The success in the sector often hinges on progressive and often groundbreaking medical advancements.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA
10:37am, Friday, 26'th Jul 2024
NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Moderna, Inc. (“Moderna” or the “Company”) (NASDAQ: MRNA). Such investors are a
Moderna (MRNA) Stock Before Q2 Earnings: To Buy or Not to Buy?
09:41am, Friday, 26'th Jul 2024
Investors will likely focus on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates when it reports second-quarter earnings.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA
08:00pm, Wednesday, 24'th Jul 2024
NEW YORK , July 24, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Moderna, Inc. ("Moderna" or the "Company") (NASDAQ: MRNA). Such investors are advised to con
Why Moderna (MRNA) Dipped More Than Broader Market Today
06:56pm, Tuesday, 23'rd Jul 2024
The latest trading day saw Moderna (MRNA) settling at $121.25, representing a -1.02% change from its previous close.
